Clinical Trial

Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH

Name: Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH — clinical trial record (NCT07204041)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

In adult patients with relapsed/refractory Langerhans cell histiocytosis (LCH), a treatment regimen of XTD regimen (Selinexor, Thalidomide and Dexamethasone) is planned to be used.

Trial Details

NCT Number	NCT07204041
Lead Sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions	Langerhans Cell Histiocytosis (LCH)
Enrollment	40 participants
Start Date	2025-08-01
Primary Completion	2027-08-01 (estimated)
Study Completion	2027-08-02 (estimated)
Updated on ClinicalTrials.gov	2025-10-02